Information  X 
Enter a valid email address

ValiRx reports progress on novel cancer drug

By BFN News | 09:01 AM | Tuesday 02 September, 2014

ValiRx Plc (AIM: VAL), the life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, has provided a further development and scientific update on the progress of pre-clinical studies at ValiSeek, its joint venture company with Tangent Reprofiling. ValiSeek was formed to develop VAL401, the novel lung cancer treatment drug, through its remaining preclinical development and towards clinical efficacy (Phase II) trials for the treatment of lung cancer and potentially other oncology indications. It has now completed the efficacy phase of pre-clinical testing for the use of VAL401 in non-small cell lung cancer. Studies demonstrated a mean response with at least a 50% reduction in the rate of tumour growth in an accepted standard cancer model. Furthermore, no adverse effects were seen during the course of the experiment, which comprised six weeks of continuous treatment at three differing dose levels. The company believes that these positive and exciting results confirm the promise shown by the earlier reported cellular assay results. Further efficacy studies will be carried out in due course to establish the potential utility of VAL401 and its broad spectrum use against solid adenocarcinoma tumours or cancers of hormone responsive glandular origin, which include prostate, breast and pancreatic cancers and other small cell lung cancers. Dr Satu Vainikka, CEO of ValiRx, added: "The ValiSeek pre-clinical efficacy results are highly encouraging and progress VAL401 further down its remaining pre-clinical development pipeline. This adds commercial value and further enhances ValiRx's portfolio of treatments for multiple cancer indications. I look forward to VAL401's continued future enhancement and progress through clinical trials." At 9:01am: (LON:VAL) ValiRx PLC share price was +0.06p at 0.45p Story provided by

a d v e r t i s e m e n t